{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:46:06Z","timestamp":1793781966961,"version":"4.6.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tech Coloproctol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10151-024-02953-z","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T09:01:35Z","timestamp":1721466095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Infliximab serum concentrations and disease activity in perianal fistulizing Crohn\u2019s disease: a cross-sectional study"],"prefix":"10.1007","volume":"28","author":[{"given":"E. F.","family":"Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. B.","family":"Nones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. B.","family":"Bara\u00fana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"de Nardi Mar\u00e7al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Olandoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. P.","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. G.","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"issue":"6","key":"2953_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55(6):749\u2013753","journal-title":"Gut"},{"issue":"10114","key":"2953_CR2","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N et al (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390(10114):2769\u20132778","journal-title":"Lancet"},{"issue":"9","key":"2953_CR3","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.cgh.2006.06.021","volume":"4","author":"LY Tang","year":"2006","unstructured":"Tang LY, Rawsthorne P, Bernstein CN (2006) Are perineal and luminal fistulas associated in Crohn\u2019s disease? A population-based study. Clin Gastroenterol Hepatol 4(9):1130\u20131134","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2953_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/ecco-jcc\/jjw144","volume":"11","author":"AL Hart","year":"2017","unstructured":"Hart AL, Lomer M, Verjee A et al (2017) What are the top 10 research questions in the treatment of inflammatory bowel disease? A priority setting partnership with the James Lind Alliance. J Crohns Colitis 11(2):204\u2013211","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2953_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2036.2010.04486.x","volume":"33","author":"PJ Tozer","year":"2011","unstructured":"Tozer PJ, Burling D, Gupta A, Phillips RK, Hart AL (2011) Review article: medical, surgical and radiological management of perianal Crohn\u2019s fistulas. Aliment Pharmacol Ther 33(1):5\u201322","journal-title":"Aliment Pharmacol Ther"},{"issue":"18","key":"2953_CR6","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 340(18):1398\u20131405","journal-title":"N Engl J Med"},{"issue":"2","key":"2953_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00054725-200303000-00003","volume":"9","author":"M Regueiro","year":"2003","unstructured":"Regueiro M, Mardini H (2003) Treatment of perianal fistulizing Crohn\u2019s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 9(2):98\u2013103","journal-title":"Inflamm Bowel Dis"},{"key":"2953_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","volume":"10","author":"EA Maser","year":"2006","unstructured":"Maser EA, Villela R, Silverberg MS, Greenberg GR (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease. Clin Gastroenterol Hepatol 10:1248\u20131254","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2953_CR9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s10620-018-5362-3","volume":"64","author":"M Chaparro","year":"2019","unstructured":"Chaparro M, Barreiro-de Acosta M, Echarri A et al (2019) Correlation between anti-TNF serum levels and endoscopic inflammation in inflammatory bowel disease patients. Dig Dis Sci 64(3):846\u2013854","journal-title":"Dig Dis Sci"},{"issue":"7","key":"2953_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/apt.13754","volume":"44","author":"T Billiet","year":"2016","unstructured":"Billiet T, Cleynen I, Ballet V et al (2016) Prognostic factors for long-term infliximab treatment in Crohn\u2019s disease patients: a 20-year single centre experience. Aliment Pharmacol Ther 44(7):673\u2013683","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2953_CR11","first-page":"549","volume":"11","author":"Y Davidov","year":"2017","unstructured":"Davidov Y, Ungar B, Bar-Yoseph H et al (2017) Association of induction infliximab levels with clinical response in perianal Crohn\u2019s disease. J Crohns Colitis 11(5):549\u2013555","journal-title":"J Crohns Colitis"},{"issue":"7","key":"2953_CR12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/apt.13970","volume":"45","author":"AJ Yarur","year":"2017","unstructured":"Yarur AJ, Kanagala V, Stein DJ et al (2017) Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn\u2019s disease. Aliment Pharmacol Ther 45(7):933\u2013940","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2953_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/00365521.2019.1600014","volume":"54","author":"AS Strik","year":"2019","unstructured":"Strik AS, L\u00f6wenberg M, Buskens CJ et al (2019) Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn\u2019s disease patients. Scand J Gastroenterol 54(4):453\u2013458","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"2953_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/ibd\/izy217","volume":"25","author":"W El-Matary","year":"2019","unstructured":"El-Matary W, Walters TD, Huynh HQ et al (2019) Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal Crohn\u2019s disease in children. Inflamm Bowel Dis 25(1):150\u2013155","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"2953_CR15","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/ecco-jcc\/jjy087","volume":"12","author":"FM Ruemmele","year":"2018","unstructured":"Ruemmele FM, Rosh J, Faubion WA et al (2018) Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn\u2019s disease: results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis 12(10):1249\u20131254","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2953_CR16","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/ibd\/izy320","volume":"25","author":"N Plevris","year":"2019","unstructured":"Plevris N, Lyons M, Jenkinson PW et al (2019) Higher adalimumab drug levels during maintenance therapy for Crohn\u2019s disease are associated with biologic remission. Inflamm Bowel Dis 25(6):1036\u20131043","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"2953_CR17","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1093\/ibd\/izy132","volume":"24","author":"K Papamichael","year":"2018","unstructured":"Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT (2018) Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn\u2019s disease. Inflamm Bowel Dis 24(10):2266\u20132271","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"2953_CR18","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.cgh.2021.07.053","volume":"20","author":"M De Gregorio","year":"2022","unstructured":"De Gregorio M, Lee T, Krishnaprasad K, Amos G, An YK, Bastian-Jordan M (2022) Higher anti-tumor necrosis factor-\u03b1 levels correlate with improved radiologic outcomes in Crohn\u2019s perianal fistulas. Clin Gastroenterol Hepatol 20(6):1306\u20131314","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"83","key":"2953_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20830","volume":"20","author":"K Freeman","year":"2016","unstructured":"Freeman K, Connock M, Auguste P et al (2016) Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-\u03b1) inhibitors [LISA-TRACKER\u00ae enzyme-linked immunosorbent assay (ELISA) kits, TNF-\u03b1-Blocker ELISA kits and Promonitor\u00ae ELISA kits] versus standard care in patients with Crohn\u2019s disease: systematic reviews and economic modelling. Health Technol Assess 20(83):1\u2013288","journal-title":"Health Technol Assess"},{"issue":"10","key":"2953_CR20","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1515\/cclm-2012-0050","volume":"50","author":"F Llinares-Tello","year":"2012","unstructured":"Llinares-Tello F, de Salazar JR, Gallego JM et al (2012) Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med 50(10):1845\u20131847","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"2953_CR21","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1515\/cclm-2013-0461","volume":"51","author":"B Ruiz-Arg\u00fcello","year":"2013","unstructured":"Ruiz-Arg\u00fcello B, del Agua AR, Torres N, Monasterio A, Mart\u00ednez A, Nagore D (2013) Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 51(12):e287\u2013e289","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"2953_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00330-014-3111-3","volume":"24","author":"JA Tielbeek","year":"2014","unstructured":"Tielbeek JA, Bipat S, Boellaard TN, Nio CY, Stoker J (2014) Training readers to improve their accuracy in grading Crohn\u2019s disease activity on MRI. Eur Radiol 24(5):1059\u20131067","journal-title":"Eur Radiol"},{"issue":"7","key":"2953_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10151-017-1647-3","volume":"21","author":"GC Braithwaite","year":"2017","unstructured":"Braithwaite GC, Lee MJ, Hind D, Brown SR (2017) Prognostic factors affecting outcomes in fistulating perianal Crohn\u2019s disease: a systematic review. Tech Coloproctol 21(7):501\u2013519","journal-title":"Tech Coloproctol"},{"issue":"5","key":"2953_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.14309\/ajg.0000000000001111","volume":"116","author":"K Papamichael","year":"2021","unstructured":"Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS (2021) Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn\u2019s disease: an ACCENT-II post hoc analysis. Am J Gastroenterol 116(5):1007\u20131014","journal-title":"Am J Gastroenterol"},{"issue":"23","key":"2953_CR25","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.3748\/wjg.v28.i23.2597","volume":"28","author":"B Gu","year":"2022","unstructured":"Gu B, Venkatesh K, Williams AJ et al (2022) Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn\u2019s disease. World J Gastroenterol 28(23):2597\u20132608","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2953_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S2468-1253(22)00007-3","volume":"7","author":"J Geldof","year":"2022","unstructured":"Geldof J, Iqbal N, LeBlanc JF et al (2022) Classifying perianal fistulising Crohn\u2019s disease: an expert consensus to guide decision-making in daily practice and clinical trials. Lancet Gastroenterol Hepatol 7(6):576\u2013584","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Techniques in Coloproctology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10151-024-02953-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10151-024-02953-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10151-024-02953-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:03:08Z","timestamp":1733936588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10151-024-02953-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2953"],"URL":"https:\/\/doi.org\/10.1007\/s10151-024-02953-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3982992\/v1","asserted-by":"object"}]},"ISSN":["1123-6337","1128-045X"],"issn-type":[{"value":"1123-6337","type":"print"},{"value":"1128-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"assertion":[{"value":"23 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PGK has received consultancy and speaking honoraria, from Abbvie, Janssen, Pfizer and Takeda. He also received scientific grants from Pfizer and Takeda and performs clinical research for Ventyx. EFM is a speaker for Abbvie, Janssen and Takeda. All other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Research Ethics Committee of the Pontifical Catholic University of Paran\u00e1 via Plataforma Brazil website, under reference number 13812619.7.0000.0020.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The informed consent form was obtained after the participants and\/or legal guardians had been sufficiently informed of all the possible benefits and risks, in addition to guidance.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"86"}}